ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagenaar, M.
Right arrow Articles by Folgering, H.T.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagenaar, M.
Right arrow Articles by Folgering, H.T.M.
Eur Respir J 2002; 20:1130-1137
Copyright ©ERS Journals Ltd 2002


Combined treatment with acetazolamide and medroxyprogesterone in chronic obstructive pulmonary disease patients

M. Wagenaar1, P. Je Vos1, Y.F. Heijdra1, L.J. Teppema2 and H.T.M. Folgering1

1 Dept of Pulmonary Diseases, Dekkerswald, University of Nijmegen, Nijmegen, and 2 Dept of Physiology, Leiden University Medical Centre, Leiden, the Netherlands

CORRESPONDENCE: M. Wagenaar, Dept of Pulmonary Diseases, Dekkerswald, University of Nijmegen, P.O. Box 9001, 6560 GB, Groesbeek, The Netherlands. Fax: 31 246859290. E-mail: m.wagenaar@ulc.azn.nl

Keywords: acetazolamide, chronic obstructive pulmonary disease, hypercapnia, medroxyprogesterone acetate

Received: February 25, 2002
Accepted July 2, 2002

This study was funded by the Netherlands Asthma Foundation.

Medroxyprogesterone acetate (MPA) and acetazolamide (ACET) are two ventilatory stimulants which are used in hypoxic and hypercapnic patients with chronic obstructive pulmonary disease (COPD).

In a double-blind randomised study, the effects of a 2-week treatment with MPA (30 mg b.i.d.) or ACET (250 mg b.i.d.), followed by a 2-week treatment with a combination of both drugs (MPA/ACET), on daytime and nocturnal ventilatory and blood gas parameters in 17 stable hypercapnic COPD patients were investigated.

ACET, MPA and MPA/ACET treatment decreased mean daytime carbon dioxide tension in arterial blood by 0.4, 0.7 and 1.2 kPa, respectively. Minute ventilation was improved only with combined therapy, from 9.3 to 11.2 L·min–1.

With MPA/ACET therapy, the hypercapnic and hypoxic ventilatory responses significantly increased, from 3.7 to 5.8 L·min–1·kPa–1 and from –0.13 to –0.40 L·min–1·%–1, respectively. The mouth exclusion pressure response to hypoxia increased during combination therapy, from –0.01 to –0.03 kPa·%–1. Nocturnal end-tidal carbon dioxide tension decreased with MPA and MPA/ACET treatment, by 0.9 and 1.4 kPa, respectively. MPA/ACET significantly increased mean nocturnal arterial oxygen saturation values, from 85.5 to 90.2%.

The authors conclude that short-term combined treatment with medroxyprogesterone acetate and acetazolamide has a more favourable effect on day and night-time blood gas values and chemical drive than single drug treatment.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
M. J Bales and E. M Timpe
Respiratory Stimulant Use in Chronic Obstructive Pulmonary Disease
Ann. Pharmacother., October 1, 2004; 38(10): 1722 - 1725.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R.P. Cole
Carbon dioxide production during acetazolamide and medroxyprogesterone treatment
Eur. Respir. J., April 1, 2003; 21(4): 733 - 733.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the European Respiratory Society.